Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.
J Clin Invest
; 130(3): 1288-1300, 2020 03 02.
Article
en En
| MEDLINE
| ID: mdl-31743109
ABSTRACT
Immune response to therapeutic enzymes poses a detriment to patient safety and treatment outcome. Enzyme replacement therapy (ERT) is a standard therapeutic option for some types of mucopolysaccharidoses, including Morquio A syndrome caused by N-acetylgalactosamine-6-sulfate sulfatase (GALNS) deficiency. Current protocols tolerize patients using cytotoxic immunosuppressives, which can cause adverse effects. Here we show development of tolerance in Morquio A mice via oral delivery of peptide or GALNS for 10 days prior to ERT. Our results show that using an immunodominant peptide (I10) or the complete GALNS enzyme to orally induce tolerance to GALNS prior to ERT resulted in several improvements to ERT in mice (a) decreased splenocyte proliferation after in vitro GALNS stimulation, (b) modulation of the cytokine secretion profile, (c) decrease in GALNS-specific IgG or IgE in plasma, (d) decreased GAG storage in liver, and (e) fewer circulating immune complexes in plasma. This model could be extrapolated to other lysosomal storage disorders in which immune response hinders ERT.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Péptidos
/
Condroitinsulfatasas
/
Desensibilización Inmunológica
/
Mucopolisacaridosis IV
/
Terapia de Reemplazo Enzimático
/
Tolerancia Inmunológica
Tipo de estudio:
Guideline
Límite:
Animals
/
Humans
Idioma:
En
Revista:
J Clin Invest
Año:
2020
Tipo del documento:
Article
País de afiliación:
Estados Unidos